Functional proteomic analysis reveals the involvement of KIAA1199 in breast cancer growth, motility and invasiveness

BMC Cancer

Mohammad-Saeid Jami¹  Jinxuan Hou⁵  Miao Liu¹  Michelle L Varney¹  Hesham Hassan¹  Jixin Dong³  Liying Geng³  Jing Wang³  Fang Yu⁴  Xin Huang¹  Hong Peng¹  Kai Fu¹  Yan Li⁵  Rakesh K Singh¹  Shi-Jian Ding² 

[1] Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE 68198, USA

[2] Biomarker Discovery and Development Laboratory, Sanford-Burnham Medical Research Institute at Lake Nona, Orlando, FL 32827, USA

[3] Eppley Cancer Institute, University of Nebraska Medical Center, Omaha, NE 68198, USA

[4] Department of Biostatistics, University of Nebraska Medical Center, Omaha, NE 68198, USA

[5] Department of Oncology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China

关键词: Quantitative proteomic analysis;    KIAA1199;    Breast cancer;   

Others  :  858962
DOI  :  10.1186/1471-2407-14-194

 received in 2013-08-29, accepted in 2014-03-03,  发布年份 2014

【 摘 要 】

Background

KIAA1199 is a recently identified novel gene that is up-regulated in human cancer with poor survival. Our proteomic study on signaling polarity in chemotactic cells revealed KIAA1199 as a novel protein target that may be involved in cellular chemotaxis and motility. In the present study, we examined the functional significance of KIAA1199 expression in breast cancer growth, motility and invasiveness.

Methods

We validated the previous microarray observation by tissue microarray immunohistochemistry using a TMA slide containing 12 breast tumor tissue cores and 12 corresponding normal tissues. We performed the shRNA-mediated knockdown of KIAA1199 in MDA-MB-231 and HS578T cells to study the role of this protein in cell proliferation, migration and apoptosis in vitro. We studied the effects of KIAA1199 knockdown in vivo in two groups of mice (n = 5). We carried out the SILAC LC-MS/MS based proteomic studies on the involvement of KIAA1199 in breast cancer.

Results

KIAA1199 mRNA and protein was significantly overexpressed in breast tumor specimens and cell lines as compared with non-neoplastic breast tissues from large-scale microarray and studies of breast cancer cell lines and tumors. To gain deeper insights into the novel role of KIAA1199 in breast cancer, we modulated KIAA1199 expression using shRNA-mediated knockdown in two breast cancer cell lines (MDA-MB-231 and HS578T), expressing higher levels of KIAA1199. The KIAA1199 knockdown cells showed reduced motility and cell proliferation in vitro. Moreover, when the knockdown cells were injected into the mammary fat pads of female athymic nude mice, there was a significant decrease in tumor incidence and growth. In addition, quantitative proteomic analysis revealed that knockdown of KIAA1199 in breast cancer (MDA-MB-231) cells affected a broad range of cellular functions including apoptosis, metabolism and cell motility.

Conclusions

Our findings indicate that KIAA1199 may play an important role in breast tumor growth and invasiveness, and that it may represent a novel target for biomarker development and a novel therapeutic target for breast cancer.

【 授权许可】

   
2014 Jami et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Jemal A, Siegel R, Xu J, Ward E: Cancer statistics. CA Cancer J Clin 2010, 60(5):277-300.
• [2]Karnoub AE, Weinberg RA: Chemokine networks and breast cancer metastasis. Breast Dis 2006, 26:75-85.
• [3]Wang Y, Ding SJ, Wang W, Jacobs JM, Qian WJ, Moore RJ, Yang F, Camp DG II, Smith RD, Klemke RL: Profiling signaling polarity in chemotactic cells. Proc Natl Acad Sci USA 2007, 104:8328-8333.
• [4]Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW: A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006, 10:515-527.
• [5]Abe S, Usami S, Nakamura Y: Mutations in the gene encoding KIAA1199 protein, an inner-ear protein expressed in Deiters’ cells and the fibrocytes, as the cause of nonsyndromic hearing loss. J Hum Genet 2003, 48:564-570.
• [6]Paunu N, Lahermo P, Onkamo P, Ollikainen V, Rantala I, Helen P, Simola KO, Kere J, Haapasalo H: A novel low-penetrance locus for familial glioma at 15q23-q26.3. Cancer Res 2002, 62:3798-3802.
• [7]Kao J, Salari K, Bocanegra M, Choi YL, Girard L, Gandhi J, Kwei KA, Hernandez-Boussard T, Wang P, Gazdar AF, Minna JD, Pollack JR: Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One 2009, 4:e6146.
• [8]Matsuzaki S, Tanaka F, Mimori K, Tahara K, Inoue H, Mori M: Clinicopathologic significance of KIAA1199 overexpression in human gastric cancer. Ann Surg Oncol 2009, 16:2042-2051.
• [9]Birkenkamp-Demtroder K, Maghnouj A, Mansilla F, Thorsen K, Andersen CL, Oster B, Hahn S, Orntoft TF: Repression of KIAA1199 attenuates Wnt-signalling and decreases the proliferation of colon cancer cells. Br J Cancer 2011, 105:552-561.
• [10]Michishita E, Garces G, Barrett JC, Horikawa I: Upregulation of the KIAA1199 gene is associated with cellular mortality. Cancer Lett 2006, 239:71-77.
• [11]Kostic C, Shaw PH: Isolation and characterization of sixteen novel p53 response genes. Oncogene 2000, 19:3978-3987.
• [12]Ding SJ, Li Y, Tan YX, Jiang MR, Tian B, Liu YK, Shao XX, Ye SL, Wu JR, Zeng R, Wang HY, Tang ZY, Xia QC: From proteomic analysis to clinical significance: overexpression of cytokeratin 19 correlates with hepatocellular carcinoma metastasis. Mol Cell Proteomics 2004, 3:73-81.
• [13]Jami M-S, Barreiro C, García-Estrada C, Martín J-F: Proteome analysis of the penicillin producer Penicillium chrysogenum: characterization of protein changes during the industrial strain improvement. Mol Cell Proteomics MCP 2010, 9:1182-1198.
• [14]Hou J, Dong J, Sun L, Geng L, Wang J, Zheng J, Li Y, Bridge J, Hinrichs SH, Ding SJ: Inhibition of phosphorylated c-Met in rhabdomyosarcoma cell lines by a small molecule inhibitor SU11274. J Transl Med 2011, 9:64. BioMed Central Full Text
• [15]Varney ML, Johansson SL, Singh RK: Distinct expression of CXCL8 and its receptors CXCR1 and CXCR2 and their association with vessel density and aggressiveness in malignant melanoma. Am J Clin Pathol 2006, 125:209-216.
• [16]Huang X, Tolmachev AV, Shen Y, Liu M, Huang L, Zhang Z, Anderson GA, Smith RD, Chan WC, Hinrichs SH, Fu K, Ding SJ: UNiquant, a program for quantitative proteomics analysis using stable isotope labeling. J Proteome Res 2011, 10:1228-1237.
• [17]Benjamini Y, Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc 1995, 57:289-300.
• [18]Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS: Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009, 27:1160-1167.
• [19]Gluck S, Ross JS, Royce M, Jr ME F, Perou CM, Avisar E, Wu L: TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine +/− trastuzumab. Breast Cancer Res Treat 2011, 132(3):781-791. 2011/03/05
• [20]Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A, Liao X, Iglehart JD, Livingston DM, Ganesan S: X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 2006, 9:121-132.
• [21]Elmore S: Apoptosis: a review of programmed cell death. Toxicol Pathol 2007, 35:495-516.
• [22]Oltvai ZN, Milliman CL, Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993, 74:609-619.
• [23]Schmitt E, Paquet C, Beauchemin M, Dever-Bertrand J, Bertrand R: Characterization of Bax-sigma, a cell death-inducing isoform of Bax. Biochem Biophys Res Commun 2000, 270:868-879.
• [24]Chittenden T, Flemington C, Houghton AB, Ebb RG, Gallo GJ, Elangovan B, Chinnadurai G, Lutz RJ: A conserved domain in Bak, distinct from BH1 and BH2, mediates cell death and protein binding functions. Embo J 1995, 14:5589-5596.
• [25]Chinnaiyan AM, O’Rourke K, Tewari M, Dixit VM: FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995, 81:505-512.
• [26]Garcia-Domingo D, Leonardo E, Grandien A, Martinez P, Albar JP, Izpisua-Belmonte JC, Martinez AC: DIO-1 is a gene involved in onset of apoptosis in vitro, whose misexpression disrupts limb development. Proc Natl Acad Sci USA 1999, 96:7992-7997.
• [27]Kamada S, Kikkawa U, Tsujimoto Y, Hunter T: A-kinase-anchoring protein 95 functions as a potential carrier for the nuclear translocation of active caspase 3 through an enzyme-substrate-like association. Mol Cell Biol 2005, 25:9469-9477.
• [28]Peluso JJ, Romak J, Liu X: Progesterone receptor membrane component-1 (PGRMC1) is the mediator of progesterone’s antiapoptotic action in spontaneously immortalized granulosa cells as revealed by PGRMC1 small interfering ribonucleic acid treatment and functional analysis of PGRMC1 m. Endocrinology 2008, 149:534-543.
• [29]Crudden G, Loesel R, Craven RJ: Overexpression of the cytochrome p450 activator hpr6 (heme-1 domain protein/human progesterone receptor) in tumors. Tumour Biol 2005, 26:142-146.
• [30]Tai YT, Lee S, Niloff E, Weisman C, Strobel T, Cannistra SA: BAX protein expression and clinical outcome in epithelial ovarian cancer. J Clin Oncol 1998, 16:2583-2590.
• [31]He H, Li J, Weng S, Li M, Yu Y: S100A11: diverse function and pathology corresponding to different target proteins. Cell Biochem Biophys 2009, 55:117-126.
• [32]Still IH, Vince P, Cowell JK: The third member of the transforming acidic coiled coil-containing gene family, TACC3, maps in 4p16, close to translocation breakpoints in multiple myeloma, and is upregulated in various cancer cell lines. Genomics 1999, 58:165-170.
• [33]Schneider L, Essmann F, Kletke A, Rio P, Hanenberg H, Schulze-Osthoff K, Nurnberg B, Piekorz RP: TACC3 depletion sensitizes to paclitaxel-induced cell death and overrides p21WAF-mediated cell cycle arrest. Oncogene 2008, 27:116-125.
• [34]Takenawa T, Suetsugu S: The WASP-WAVE protein network: connecting the membrane to the cytoskeleton. Nat Rev Mol Cell Biol 2007, 8:37-48.
• [35]Sagara M, Kawasaki Y, Iemura SI, Natsume T, Takai Y, Akiyama T: Asef2 and Neurabin2 cooperatively regulate actin cytoskeletal organization and are involved in HGF-induced cell migration. Oncogene 2009, 28:1357-1365.
• [36]Egging D, van den Berkmortel F, Taylor G, Bristow J, Schalkwijk J: Interactions of human tenascin-X domains with dermal extracellular matrix molecules. Arch Dermatol Res 2007, 298:389-396.
• [37]Hughes L, Malone C, Chumsri S, Burger AM, McDonnell S: Characterisation of breast cancer cell lines and establishment of a novel isogenic subclone to study migration, invasion and tumourigenicity. Clin Exp Metastasis 2008, 25:549-557.
• [38]Jin L, Williamson A, Banerjee S, Philipp I, Rape M: Mechanism of ubiquitin-chain formation by the human anaphase-promoting complex. Cell 2008, 133:653-665.
• [39]Lee JH, You J, Dobrota E, Skalnik DG: Identification and characterization of a novel human PP1 phosphatase complex. J Biol Chem 2010, 285:24466-24476.
• [40]Tang Z, Shu H, Qi W, Mahmood NA, Mumby MC, Yu H: PP2A is required for centromeric localization of Sgo1 and proper chromosome segregation. Dev Cell 2006, 10:575-585.
• [41]Warburg O: On the origin of cancer cells. Science (80-) 1956, 123:309-314.
• [42]DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB: The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008, 7:11-20.